IBOGF (Universal Ibogaine) EV-to-EBIT: -11.18 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Universal Ibogaine EV-to-EBIT?

Universal Ibogaine IBOGF +7.56% EV-to-EBIT is -11.18 as of Jul. 14, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Universal Ibogaine's Enterprise Value is $10.62 Mil. Universal Ibogaine's EBIT for the trailing twelve months (TTM) ended in Apr. 2025 was $-0.95 Mil. Therefore, Universal Ibogaine's EV-to-EBIT for today is -11.18.

The historical rank and industry rank for Universal Ibogaine's EV-to-EBIT or its related term are showing as below:

IBOGF' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.33   Med: 0   Max: 0
Current: -11.18
IBOGF's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 13.76 vs IBOGF: -11.18

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Universal Ibogaine's Enterprise Value for the quarter that ended in Apr. 2025 was $8.48 Mil. Universal Ibogaine's EBIT for the trailing twelve months (TTM) ended in Apr. 2025 was $-0.95 Mil. Universal Ibogaine's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2025 was -11.21%.

Universal Ibogaine  (OTCPK:IBOGF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Universal Ibogaine's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Apr. 2025 ) =EBIT / Enterprise Value (Q: Apr. 2025 )
=-0.95/8.4757198
=-11.21 %

Universal Ibogaine's Enterprise Value for the quarter that ended in Apr. 2025 was $8.48 Mil.
Universal Ibogaine's EBIT for the trailing twelve months (TTM) ended in Apr. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine EV-to-EBIT Related Terms

Universal Ibogaine EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine EV-to-EBIT Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
EV-to-EBIT
Get a 7-Day Free Trial -29.03 -24.30 -0.83 -2.35 -3.67

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.58 -3.67 -2.78 -4.02 -8.29

IBOGF vs LABT, CALC, LNAI: EV-to-EBIT Comparison

For the Biotechnology subindustry, Universal Ibogaine's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's EV-to-EBIT falls into.


Universal Ibogaine EV-to-EBIT Calculation

Universal Ibogaine's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10.621/-0.95
=-11.18

Universal Ibogaine's current Enterprise Value is $10.62 Mil.
Universal Ibogaine's EBIT for the trailing twelve months (TTM) ended in Apr. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of -11.18 mean?
Universal Ibogaine (IBOGF) has a EV-to-EBIT of -11.18 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's EV-to-EBIT too high?
Universal Ibogaine's current EV-to-EBIT is -11.18.
How does Universal Ibogaine's EV-to-EBIT compare to LABT and CALC?
Universal Ibogaine's EV-to-EBIT of -11.18 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 13.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.76, based on 371 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Universal Ibogaine and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universal Ibogaine's current EV-to-EBIT is -11.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current EV-to-EBIT of -11.18. The current EV-to-EBIT is -11.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current EV-to-EBIT is -11.18 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.